{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:03:24Z","timestamp":1791875004130,"version":"4.3.4"},"reference-count":48,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016015","name":"Universit\u00e4tsspital Basel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.cmi.2025.04.046","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T13:11:47Z","timestamp":1746796307000},"page":"1484-1490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Herpes simplex virus and drug resistance\u2014comprehensive update on resistance mutations and implications for clinical management: a narrative review"],"prefix":"10.1016","volume":"31","author":[{"given":"Theo","family":"D\u00e4hne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Jaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Gosert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Fuchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andi","family":"Krumbholz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaudia","family":"N\u00e4gele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias W.","family":"Pletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline","family":"Leuzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Panning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2025.04.046_bib1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1146\/annurev-micro-092412-155654","article-title":"An inquiry into the molecular basis of HSV latency and reactivation","volume":"67","author":"Roizman","year":"2013","journal-title":"Annu Rev Microbiol"},{"key":"10.1016\/j.cmi.2025.04.046_bib2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1056\/NEJM198107093050202","article-title":"Acyclovir prophylaxis of herpes-simplex-virus infections","volume":"305","author":"Saral","year":"1981","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cmi.2025.04.046_bib3","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1177\/09564624211006568","article-title":"Use of pritelivir in refractory aciclovir-resistant herpes simplex virus type 2","volume":"32","author":"Cannon","year":"2021","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.cmi.2025.04.046_bib4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cmi.2019.09.003","article-title":"Anti-herpesvirus prophylaxis, pre-emptive treatment or no treatment in adults undergoing allogeneic transplant for haematological disease: systematic review and meta-analysis","volume":"26","author":"Beyar-Katz","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2025.04.046_bib5","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1086\/314052","article-title":"Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation","volume":"31","author":"Chen","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.046_bib6","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2574","article-title":"Management of refractory\/resistant herpes simplex virus infections in haematopoietic stem cell transplantation recipients: a literature review","volume":"34","author":"Sall\u00e9e","year":"2024","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.cmi.2025.04.046_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2020.104421","article-title":"Challenges of aciclovir-resistant HSV infection in allogeneic bone marrow transplant recipients","volume":"128","author":"Anton-Vazquez","year":"2020","journal-title":"J Clin Virol"},{"key":"10.1016\/j.cmi.2025.04.046_bib8","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1128\/JCM.42.1.242-249.2004","article-title":"Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up","volume":"42","author":"Danve-Szatanek","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.cmi.2025.04.046_bib9","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/infdis\/jix042","article-title":"Association of the emergence of acyclovir-resistant herpes simplex virus type 1 with prognosis in hematopoietic stem cell transplantation patients","volume":"215","author":"Kakiuchi","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.046_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciae638","article-title":"Refractory and resistant herpes simplex virus mucocutaneous infections in immunocompromised patients: literature review and proposed definitions for use in clinical trials","author":"Chemaly","year":"2025","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.046_bib50","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1086\/518938","article-title":"Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease","volume":"196","author":"Erard","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.046_bib11","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/jac\/dkv285","article-title":"Database on natural polymorphisms and resistance-related non-synonymous mutations in thymidine kinase and DNA polymerase genes of herpes simplex virus types 1 and 2","volume":"71","author":"Sauerbrei","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.cmi.2025.04.046_bib12","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1128\/AAC.33.8.1375","article-title":"Continuous infusion of high-dose acyclovir for serious herpesvirus infections","volume":"33","author":"Fletcher","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2025.04.046_bib13","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1001\/jama.1990.03440120084042","article-title":"Treatment of resistant herpes simplex virus with continuous-infusion acyclovir","volume":"263","author":"Engel","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2025.04.046_bib14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0732-8893(87)90005-8","article-title":"Progressive mucocutaneous herpes simplex infection due to acyclovir-resistant virus in an immunocompromised patient: correlation of viral susceptibilities and plasma levels with response to therapy","volume":"7","author":"Bean","year":"1987","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.046_bib15","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.bbmt.2010.06.020","article-title":"Treatment of acyclovir-resistant herpes simplex virus with continuous infusion of high-dose acyclovir in hematopoietic cell transplant patients","volume":"17","author":"Kim","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cmi.2025.04.046_bib16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0924-8579(95)00008-V","article-title":"Pharmacology and clinical use of foscarnet","volume":"5","author":"G\u00e9rard","year":"1995","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.cmi.2025.04.046_bib17","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/CCM.0b013e3181961bff","article-title":"Pharmacokinetic issues for antibiotics in the critically ill patient","volume":"37","author":"Roberts","year":"2009","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cmi.2025.04.046_bib18","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/cc7774","article-title":"Bench-to-bedside review: appropriate antibiotic therapy in severe sepsis and septic shock \u2013 does the dose matter?","volume":"13","author":"Pea","year":"2009","journal-title":"Crit Care"},{"key":"10.1016\/j.cmi.2025.04.046_bib19","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S1474-4422(18)30244-8","article-title":"Frequency, symptoms, risk factors, and outcomes of autoimmune encephalitis after herpes simplex encephalitis: a prospective observational study and retrospective analysis","volume":"17","author":"Armangue","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.cmi.2025.04.046_bib20","doi-asserted-by":"crossref","DOI":"10.1093\/ve\/veaa013","article-title":"In vitro evolution of herpes simplex virus 1 (HSV-1) reveals selection for syncytia and other minor variants in cell culture","volume":"6","author":"Kuny","year":"2020","journal-title":"Virus Evol"},{"key":"10.1016\/j.cmi.2025.04.046_bib21","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1093\/infdis\/jiae414","article-title":"Revealing the unseen: next-generation sequencing for early detection of drug-resistant cytomegalovirus variants upon letermovir prophylaxis failure","volume":"231","author":"N\u00e4gele","year":"2025","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.046_bib22","doi-asserted-by":"crossref","first-page":"334","DOI":"10.21037\/atm.2016.09.19","article-title":"Treatment for hepatitis B in patients with drug resistance","volume":"4","author":"Tacke","year":"2016","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.cmi.2025.04.046_bib23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jviromet.2017.10.019","article-title":"Application of next-generation sequencing to detect acyclovir-resistant herpes simplex virus type 1 variants at low frequency in thymidine kinase gene of the isolates recovered from patients with hematopoietic stem cell transplantation","volume":"251","author":"Fujii","year":"2018","journal-title":"J Virol Methods"},{"key":"10.1016\/j.cmi.2025.04.046_bib43","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/0886022X.2018.1487866","article-title":"The incidence, risk factors, and clinical outcomes of acute kidney injury (staged using the RIFLE classification) associated with intravenous acyclovir administration","volume":"40","author":"Lee","year":"2018","journal-title":"Ren Fail"},{"key":"10.1016\/j.cmi.2025.04.046_bib44","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/jcpt.13464","article-title":"Neurotoxicity associated with acyclovir and valacyclovir: a systematic review of cases","volume":"46","author":"Brandariz-Nu\u00f1ez","year":"2021","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.cmi.2025.04.046_bib45","first-page":"4","article-title":"Risk of interactions between brivudine and fluoropyrimidines","volume":"1419","author":"Kern","year":"2012","journal-title":"React Wkly"},{"key":"10.1016\/j.cmi.2025.04.046_bib46","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae046","article-title":"A multicenter assessment of the outcomes and toxicities of foscarnet for treatment of acyclovir-resistant mucocutaneous herpes simplex in immunocompromised patients","volume":"11","author":"Hammond","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.046_bib47","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/infdis\/171.4.788","article-title":"(S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I\/II study of a novel antiviral nucleotide analogue","volume":"171","author":"Lalezari","year":"1995","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.046_bib48","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/eye.1999.89","article-title":"Ocular complications of intravenous cidofovir for cytomegalovirus retinitis in patients with AIDS","volume":"13","author":"Bainbridge","year":"1999","journal-title":"Eye (Lond)."},{"key":"10.1016\/j.cmi.2025.04.046_bib49","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.1021\/acs.jmedchem.7b00183","article-title":"Lead development of thiazolylsulfonamides with carbonic anhydrase inhibitory action","volume":"60","author":"Carta","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.cmi.2025.04.046_bib24","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/rmv.1787","article-title":"Antiviral drug resistance in herpesviruses other than cytomegalovirus","volume":"24","author":"Piret","year":"2014","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.cmi.2025.04.046_bib25","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/978-1-4939-0428-0_10","article-title":"Phenotypic and genotypic testing of HSV-1 resistance to antivirals","volume":"1144","author":"Sauerbrei","year":"2014","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.cmi.2025.04.046_bib26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jcv.2017.10.002","article-title":"A European multi-centre External Quality Assessment (EQA) study on phenotypic and genotypic methods used for herpes simplex virus (HSV) drug resistance testing","volume":"96","author":"Afshar","year":"2017","journal-title":"J Clin Virol"},{"key":"10.1016\/j.cmi.2025.04.046_bib27","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.idc.2010.01.001","article-title":"Antiviral drug resistance: mechanisms and clinical implications","volume":"24","author":"Strasfeld","year":"2010","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.cmi.2025.04.046_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2023.105554","article-title":"Genotypic testing improves detection of antiviral resistance in human herpes simplex virus","volume":"167","author":"Glasgow","year":"2023","journal-title":"J Clin Virol"},{"key":"10.1016\/j.cmi.2025.04.046_bib29","doi-asserted-by":"crossref","first-page":"7820","DOI":"10.1128\/JVI.77.14.7820-7829.2003","article-title":"Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids","volume":"77","author":"Bestman-Smith","year":"2003","journal-title":"J Virol"},{"key":"10.1016\/j.cmi.2025.04.046_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/srep29903","article-title":"Recombinant herpes simplex virus type 1 strains with targeted mutations relevant for aciclovir susceptibility","volume":"6","author":"Brunnemann","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.cmi.2025.04.046_bib31","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1086\/503914","article-title":"Web resources for HIV type 1 genotypic-resistance test interpretation","volume":"42","author":"Liu","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.046_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0181357","article-title":"Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation","volume":"12","author":"Paredes","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2025.04.046_bib33","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac494","article-title":"Single-dose, patient-initiated amenamevir therapy for recurrent genital herpes: a phase 3, randomized, double-blind, placebo-controlled study","volume":"9","author":"Kawashima","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.046_bib34","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3390\/v13081547","article-title":"Amenamevir, a helicase-primase inhibitor, for the optimal treatment of herpes zoster","volume":"13","author":"Shiraki","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.cmi.2025.04.046_bib35","doi-asserted-by":"crossref","first-page":"W271","DOI":"10.1093\/nar\/gky349","article-title":"geno2pheno[ngs-freq]: a genotypic interpretation system for identifying viral drug resistance using next-generation sequencing data","volume":"46","author":"D\u00f6ring","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.cmi.2025.04.046_bib36","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1086\/319231","article-title":"Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy","volume":"32","author":"Hanna","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.046_bib37","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.3390\/v7092850","article-title":"Clinical implications of antiviral resistance in influenza","volume":"7","author":"Li","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.cmi.2025.04.046_bib38","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1086\/505356","article-title":"Rationale and uses of a public HIV drug-resistance database","volume":"194","author":"Shafer","year":"2006","journal-title":"J Infect Dis"},{"key":"10.1016\/j.cmi.2025.04.046_bib39","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.antiviral.2019.05.017","article-title":"Added value of ultra-deep sequencing (UDS) approach for detection of genotypic antiviral resistance of herpes simplex virus (HSV)","volume":"168","author":"Mercier-Darty","year":"2019","journal-title":"Antivir Res"},{"key":"10.1016\/j.cmi.2025.04.046_bib40","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1093\/jac\/dkac297","article-title":"Heterogeneity and viral replication fitness of HSV-1 clinical isolates with mutations in the thymidine kinase and DNA polymerase","volume":"77","author":"Schalkwijk","year":"2022","journal-title":"J Antimicrob Chemother"}],"updated-by":[{"DOI":"10.1016\/j.cmi.2026.01.010","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000}}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X2500237X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X2500237X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T21:50:33Z","timestamp":1758664233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X2500237X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":48,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S1198743X2500237X"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2025.04.046","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Herpes simplex virus and drug resistance\u2014comprehensive update on resistance mutations and implications for clinical management: a narrative review","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2025.04.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.","name":"copyright","label":"Copyright"}]}}